Have you noticed how certain stocks just refuse to stay quiet even when the broader market feels uncertain? That is exactly the feeling I get every time Eli Lilly reports another quarter. The company keeps delivering numbers that force analysts to raise their expectations, and this latest release was no different. Shares jumped more than six percent in a single session, pushing the stock to a fresh all-time high near $1,370. For anyone who has followed the obesity-drug story over the past few years, the momentum feels almost relentless.
Why Eli Lilly Continues To Outperform Expectations
The third-quarter results painted a clear picture of strength. Revenue climbed 39 percent year over year to $24.4 billion, comfortably ahead of the $22.6 billion that most analysts had penciled in. Adjusted earnings per share came in at $7.48, beating the consensus figure of $6.26. That modest-looking percentage increase in profit actually masks a large acquisition-related charge. Once you strip that out, the underlying business looks even healthier.
Gross margin expanded to 84.4 percent, a solid improvement from both the year-ago level and the street forecast. In my view, that kind of margin expansion while volumes are exploding is one of the more impressive feats in the pharmaceutical space right now. It suggests the company is managing costs carefully even as it scales production of its blockbuster medicines.
The stock had already been up roughly 20 percent for the year heading into the report, outpacing the broader market. After a soft start to 2026 driven largely by worries about the oral obesity pill, the April earnings release marked a clear turning point. From that late-April close, shares have climbed more than 50 percent. Thursday’s numbers simply added more fuel.
The Power Of Tirzepatide Across Two Brands
Everything still revolves around tirzepatide, the molecule sold as Mounjaro for type 2 diabetes and Zepbound for obesity in the United States. Outside the U.S. the same molecule often carries the Mounjaro name for both indications. That branding difference has become increasingly important because international sales have been a consistent source of upside surprises.
Mounjaro revenue surged 65 percent to $10.7 billion in the quarter, beating estimates by about $700 million. International sales nearly doubled, rising 93 percent to $5.7 billion. Volume growth more than offset the price pressure that came with inclusion on China’s national reimbursement list. Zepbound added another $5.35 billion, up 49 percent and ahead of the $5.05 billion consensus.
What stands out to me is how both products continue to gain share in the overall GLP-1 market. Lilly’s portion of new prescriptions expanded in both the U.S. and overseas markets compared with the prior quarter. That kind of sequential share gain rarely happens by accident. It reflects strong physician confidence and patient demand that still has a long runway ahead.
Today, globally, we’d estimate maybe 3 percent of eligible patients access obesity care. In the U.S., maybe 10 percent. So the room for expansion here, of this market, is dramatic.
Those comments from the company’s chief executive capture the scale of the opportunity better than any spreadsheet. Even after years of rapid growth, the vast majority of people who could benefit from these medicines still have not started treatment. That single fact keeps me constructive on the long-term story.
Medicare Access And The Volume-Versus-Price Debate
One of the quieter but more important developments has been the temporary Medicare pilot that began in July. Eligible seniors can now obtain the drugs for $50 a month. Lilly had argued that higher volumes would more than compensate for the lower realized prices, and early evidence supports that view.
More than half a million people have already filled a prescription through the program. Among new patients entering via this channel, roughly seven out of ten start on a Lilly product. About three-quarters of them choose the injectable form. Those are strong early numbers for a program that is still in its first months.
Management’s early look at 2027 pointed to the same dynamic continuing: sustained volume growth expected to offset ongoing price headwinds. Full formal guidance will arrive with the fourth-quarter report, but the directional message is clear. The company believes the market can keep expanding fast enough to support attractive growth even with pressure on net pricing.
Foundayo Progress And The Oral Opportunity
Not every line item beat expectations. Foundayo, the oral obesity medicine that launched in the United States in April, generated $184 million in the quarter. That fell short of the $229 million consensus. The product has since reached four additional markets: the United Arab Emirates, Saudi Arabia, Mexico and the United Kingdom.
Executives described the launch as generally on track. Lilly’s share of new oral obesity prescriptions in the U.S. is approaching 40 percent. That is a solid improvement from the more-than-30-percent figure mentioned at an investor conference in mid-September. Closing the remaining gap with the competing oral product remains a priority, yet the trajectory so far feels acceptable given the later start.
Looking ahead, label expansion into type 2 diabetes and additional country launches in 2027 should provide further tailwinds. Oral therapies open the market to patients who prefer not to use injections, so any progress here expands the total addressable opportunity rather than simply shifting share from injectables.
Raised Guidance And What It Signals
Full-year 2026 guidance moved higher on both the top and bottom lines in adjusted terms. Revenue is now expected between $91 billion and $92 billion, up from the prior $85 billion to $87 billion range. Performance margin, the company’s preferred profitability metric, is guided to 52 percent to 52.5 percent versus the earlier 49 percent to 50.5 percent. Earnings-per-share guidance settled at $35 to $36.
The slight reduction in the midpoint of the EPS range reflects the accounting impact of recent acquisitions. I find that trade-off reasonable. Using today’s cash flow to fund the next generation of treatments is exactly how a company in Lilly’s position should behave. The alternative of simply harvesting the current franchise would leave the business more vulnerable over time.
Pipeline Candidates That Could Extend The Runway
Beyond the current products, two next-generation candidates stand out. Retatrutide is a triple-agonist that has generated considerable excitement in clinical data. Eloralintide represents another approach in the same broad therapeutic area. Both are the kinds of assets that can keep the growth story alive well into the next decade.
An investor day focused on research and development is scheduled for early December. That event could serve as a near-term catalyst if management provides clearer timelines or additional data cut-offs. In a market that often fixates on the next quarter, reminders of the longer pipeline help maintain perspective.
I have followed this company long enough to know that competition will intensify. Other players are advancing their own oral and injectable candidates. Pricing pressure is unlikely to disappear. Yet the combination of existing commercial strength, expanding access, and a deep pipeline still looks compelling relative to most large-cap alternatives.
Portfolio Considerations And Position Management
After more than five years of holding the stock, the original thesis has only strengthened. The potential of GLP-1 medicines to reshape treatment of obesity and diabetes remains intact. At the same time, the shares have delivered substantial gains, which means position sizing and profit-taking discipline matter more than ever.
The updated price target of $1,500 implies meaningful additional upside from current levels, yet the rating remains cautious enough to wait for a pullback before adding. That approach feels balanced. Markets rarely move in straight lines, and a stock that has already risen sharply can give back some ground on any disappointment, even temporary ones.
From a diversification standpoint, a major healthcare holding provides useful ballast when technology and artificial-intelligence names dominate headlines. The two sectors do not always move together, and that imperfect correlation can be valuable over full market cycles.
Key Risks That Still Deserve Attention
No investment story is without risks. Manufacturing capacity must keep pace with demand. Any prolonged shortfall could open the door for competitors. Regulatory decisions on future indications or pricing policies can shift the economics. Clinical setbacks on pipeline assets would also weigh on sentiment.
The oral product’s slower-than-hoped start is a reminder that not every launch unfolds perfectly. International pricing dynamics, especially in large volume markets such as China, will continue to pressure realized prices even as volumes rise. Investors need to monitor those trends carefully rather than assume the current trajectory continues forever.
- Manufacturing scale-up execution remains critical
- Competitive oral and injectable entrants are advancing
- Government pricing and reimbursement policies can change
- Pipeline candidates still face clinical and regulatory hurdles
- High expectations leave little room for operational missteps
Those points are not reasons to abandon the thesis. They are simply the realities of owning a high-growth pharmaceutical stock at elevated valuations. Awareness of the risks helps maintain discipline when the narrative inevitably faces temporary challenges.
Looking At The Bigger Market Context
The broader obesity and diabetes market is still in the early innings of a multi-year expansion. Global prevalence continues to rise. Awareness of the health consequences of excess weight has never been higher. Employers, insurers and governments are gradually recognizing the long-term cost savings that effective treatment can deliver.
Against that backdrop, Lilly sits in a privileged position. It has two of the most effective commercial products, a growing oral offering, expanding reimbursement, and a pipeline that could reset the standard of care again. Few companies can claim that combination.
I sometimes hear the argument that the easy money has already been made. There is some truth to that statement if the time horizon is measured in months. Stretch the horizon to several years, however, and the remaining opportunity still looks substantial. Penetration rates remain low. New formulations and combinations are coming. Access continues to improve.
How The Numbers Compare Across Recent Quarters
Putting the latest results in sequence helps illustrate the consistency. Each of the past several quarters has produced revenue and prescription trends that exceeded most forecasts. Margin expansion has accompanied the volume growth rather than being sacrificed for it. That pattern is rare and valuable.
| Metric | Q3 Result | Vs Consensus | YoY Change |
| Total Revenue | $24.4 billion | Beat | +39% |
| Mounjaro Sales | $10.7 billion | Beat | +65% |
| Zepbound Sales | $5.35 billion | Beat | +49% |
| Adjusted Gross Margin | 84.4% | Beat | Expanded |
| Adjusted EPS | $7.48 | Beat | +6.6% |
The table above summarizes the headline figures, but the more interesting story sits in the details of geographic mix and channel expansion. International Mounjaro growth and the early Medicare volumes both point to demand that is still broadening rather than saturating.
Personal Reflections On Holding Through Volatility
Owning a stock that makes large moves in both directions tests any investor’s temperament. There have been periods when concerns about competition or regulatory delays caused sharp pullbacks. Each time, the underlying commercial momentum eventually reasserted itself. That pattern has reinforced the value of focusing on the multi-year opportunity rather than the next few weeks of price action.
Profit-taking along the way has been part of the process. Scaling a position after large gains is simply prudent risk management. At the same time, completely exiting a name whose fundamental story continues to improve has felt premature. The balance between those two instincts is where the real work of portfolio management happens.
Perhaps the most interesting aspect of the current moment is how the narrative has shifted. A few years ago the debate centered on whether the medicines would work and whether payers would cover them. Today the conversation is about how large the market can ultimately become and which company will capture the largest share of that growth. That evolution itself is a form of progress.
What To Watch In The Coming Months
Several items sit on the near-term calendar. The December investor day should provide deeper insight into the research pipeline. Fourth-quarter results and 2027 guidance will arrive early next year. Additional data readouts on next-generation candidates could appear at medical meetings. Any updates on manufacturing capacity or international launches will also matter.
On the commercial side, tracking the monthly prescription trends for both injectables and the oral product will remain essential. Share gains or losses in new patient starts often preview the revenue numbers that follow a quarter or two later. The early experience with the Medicare pilot deserves continued attention as the program matures.
- Monitor sequential prescription share trends
- Evaluate updates from the December research day
- Assess 2027 formal guidance when released
- Watch manufacturing and supply commentary
- Track competitive clinical and commercial developments
Those checkpoints provide a practical framework for staying informed without overreacting to every daily price swing. The goal is to remain aligned with the long-term opportunity while remaining flexible enough to adjust if the facts change.
Final Thoughts On The Investment Case
Eli Lilly’s third-quarter performance reinforced the central elements of the bullish thesis. Revenue growth remains robust. Margins are expanding. Access is improving. The pipeline offers credible paths to extend the growth runway. Management continues to invest for the future rather than simply optimizing the present.
Valuation is never cheap for a company growing at this rate, and expectations are high. That combination means the path will not be linear. Pullbacks should be expected and, when the fundamentals remain intact, potentially used as opportunities rather than reasons for panic.
After watching this story unfold for more than half a decade, I still find the risk-reward profile attractive for a multi-year holding period. The obesity and diabetes treatment market is large, underpenetrated, and still evolving. Lilly sits at the center of that evolution with some of the strongest commercial assets and a research engine that has already delivered multiple breakthroughs.
The train is still moving. For those who boarded early, the ride has already been rewarding. For those considering the journey now, the destination still looks distant enough to justify the ticket price, provided the position is sized appropriately and the risks are understood. In a market searching for growth outside the usual technology names, that combination remains hard to ignore.
The numbers will keep coming every quarter. Some will beat, some may fall short. What matters most is whether the underlying demand for better obesity and diabetes care continues to expand. So far, every data point suggests it does. That is the foundation on which the entire investment case still rests.
